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INTRODUCTION 
The arterial circulation and its mechanism of control 
are remarkably well-adapted for the preservation of the entire 
organism. When blood flow to a vascular region is reduced 
by an arterial narrowing or occlusion, a series of pre­
existing alternate channels assumes the nutritive role of 
the parent artery. These alternate channels, called col­
lateral vessels, are preformed anastamosing branches of 
either functioning or nonfunctioning small arteries (Bellman 
et al., 1959; Friedenberg and Perez, 1965). In addition, 
neogenic collateral vessels may develop over a period of 
time under subacute and chronic conditions (Eriksson, 1970; 
Conrad et al., 1971). 
Collateral channels can be classified into stem, mid-
zone and reentrant vessels (Longland, 1953). Stem vessels, 
which originate proximal to a stenosis, supply blood to a 
second set called midzone vessels, which are composed of 
myriads of tiny channels normally invisible by arterio­
graphy (Winblad et al., 1959). These vessels usually have 
the greatest resistance, yet are important as they can en­
large with time and direct blood into distal reentrant 
vessels. Reentrant vessels carry retrograde blood flow 
during an arterial occlusion and join the parent vessel at 
some point distal to occlusion. The basic function of these 
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vessels is to carry blood in sufficient quantities to main­
tain the metabolic requirements (circulating equilibrium) 
of the part they serve. The extent to which the distal 
ischemic bed is preserved depends upon the capabilities of 
the collateral arteries, the site and rapidity of an arterial 
occlusion, the size, distribution, and vascular tone of 
the preformed collateral channels, and the metabolic demands 
of the tissue distal to the occlusion. 
Despite recent advances in the knowledge of peripheral 
circulation, hemodynamic changes associated with collateral 
vessel function, during health and disease, have not been 
thoroughly characterized. This is chiefly due to overly 
simplistic approaches that have been used to study collateral 
vessel recruitment and function. Some of the interpretations 
thus evolved are as follows; 
Maximum collateral blood circulation results from a 
mechanical occlusion (Eckstein et al., 1941; Winblad et al., 
1959). 
Occlusion associated with intravascular thrombosis 
depresses the collateral vessel recruitment (Schaub et al., 
1976). 
No significant improvement in blood flow occurs with 
therapeutic intervention following a mechanical obstruction 
except during strenuous exercise (Thulesius, 1963, 1972; 
Khudaiberdyerv and Kulikov, 1970). 
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Resistance across, a stenosis is dynamic and is influenced 
by peripheral and collateral hemodynamics (Roth et al., 1976; 
Walinsky et al., 1979). 
Intravascular obstruction is not purely a mechanical 
phenomenon and is always associated with endothelial cell 
damage (Turrito and Baumgartner, 1976) and ischemia (Kramer 
and Folts, 1973) which release a wide variety of vasoactive 
substances (Imhoff, 1961). These substances are believed 
to regulate the delivery of blood to the tissues (Afonso 
et al., 1974; Schaub et al., 1977a) often resulting in the 
necrosis of the part they serve (Bulle, 1957; Schaub et al., 
1977b). SRT is one substance being released during arterial 
occlusion (Bloor et al., 1973; Sullenberger et al., 1959; 
Kordenat and Kezdi, 1979). Prostanoids, another family 
of vasoactive agents also are believed to be involved during 
obstructive episodes (Alexandar et al., 1975; Ogletree and 
Lefer, 1978; Polts and Beck, 1979),. 
A wide variety of factors are involved in determination 
of the flow reserve of a vascular bed. The term "flow re­
serve" refers to maximum flow rate during oxygen deficit 
following complete occlusion. The present study was designed 
to identify and analyze the numerous interacting factors 
that affect the flow reserve of the vascular bed, and also 
to characterize collateral hemodynamics during arterial 
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stenosis. More specifically, the purposes were as follows : 
i) To determine if critical or complete stenosis of a 
vessel is associated with platelet aggregation and 
release of vasoactive substances. 
ii) To determine whether the inhibition of these 
substances by antagonists may improve the collateral 
blood flow. 
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REVIEW OP LITERATURE 
The existence of collateral circulation in an organism 
has been suggested in many different ways since the early 
second century. Antyllus (150), a great Greek surgeon, was 
first to report that the ligation of a vessel did not neces­
sarily result in loss of the part it served. Fifteen centuries 
later. Lower (1669) found that the vessels which carry blood 
to the heart were linked together by anastamosing ends which 
were later observed by Haller (1757) in his preparations. 
However, the real stimulus to the study of collateral hemo­
dynamics came following the remarkable experimental investi­
gations of Hunter, 1785 (Owen, 1861, cited in John and Warren 
(1961)), who observed a continued growth of the stag's antler, 
following ligation of the main nutrient artery, with prodigious 
development of vascular channels, that bypassed the occluded 
artery with time. From his observations, he finally concluded 
that "the vessels go, where they are needed". 
The impetus for recruitment and enlargement of collateral 
circulation has been attributed to a wide variety of factors. 
Some investigators believe that physical factors, principally 
the APS and the flow velocities, served as prime stimuli 
for the opening of preexisting collateral channels (Dornhorst 
and Schaffer, 1951; Conrad et al., 1971; Giron et al., 
1971; Barnes, 1980),. whereas others proposed that blockade 
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of sympathetic nerves potentiated the collateral circulation 
(Nothnagel, 1889; Thies, 1933; Deterling et al., 1947; Donald 
and Fergusson, 1970; Kiss et al., 1970). Still others sug­
gested that the interaction and release of vasoactive com­
pounds from the obstructed vessel and the region distal to 
it play a role in the regulation of collateral blood flow 
(Imhoff, 1961). 
A wide variety of factors are involved in the recruit­
ment of collateral vessels. The studies of different in­
vestigators will be cited in the section with an emphasis 
on the stimulus for collateral vessel recruitment and the 
role of various metabolites on collateral circulation. The 
effect of stenosis, role of prostaglandins and serotonin in 
the regulation of collateral vessel functioning will be 
reviewed in subsequent sections. 
Collateral Circulation 
In their studies on collateral flow, Lewis (1940); 
Holeman (1949); Winblad et al. (1959); John and Warren 
(1961); and Leibow (1963) stated their belief that the re­
cruitment of the collateral circulation following an inflow 
occlusion was due to interaction between increased APs, in­
creased flow velocities, vascular tone and accumulation of 
the metabolites in tissues distal to occlusion. Coffman 
(1966), however, contended that a variable response of 
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collateral recruitment was due to vasomotor tone and the 
reactivity of the collateral vessels to different vaso­
active procedures. 
Rosenthal and Guyton (1968) observed the rapid and 
major recruitment of collateral vessels during the first 
few seconds of an occlusion. This was followed by slow and 
prolonged changes over a period of time. The ensuing distal 
ischemia associated with hypotension caused vasodilatation 
of the collateral bed and suggested a possible regulatory 
role of ischemia in the modulation of collateral blood flow. 
In contrast, Thulesius (1963) could not find significant 
change in the collateral blood flow during the first few 
seconds following an occlusion, but he did notice improvement 
over the next 2-3 minutes. In their studies, peripheral vaso­
dilatation always preceded the collateral recruitment (Fleish, 
1935; Hilton, 1959) which significantly improved only during 
strenuous exercise (Khudaiberdyerv and Kulikov, 1970; 
Thulesius, 1972; Abramson, 1980). Similar findings were 
shown in the studies of Rutherford and Valenta (1971) who, 
following an exercise, observed a marked improvement in the 
muscle blood flow despite the presence of an arterial 
occlusion. 
During their experiments to ascertain the determinants 
of blood flow in a region, Mohrman and Feigl (1978) reported 
that the rate of blood flow through a region was based on the 
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interaction between the alpha adrenergic constrictor mech­
anism and the metabolism of the vascular bed involved. How­
ever, Ribeiro et al. (1979) suggested that the. oxygen induced 
increase in collateral blood to the ischemic myocardium was 
due to the protective and regulatory role of oxygen in the 
redistribution of blood flow in the region. The exact 
mechanism by which oxygen induced the increase in collateral 
blood flow could not be determined in these studies. 
Dornhorst and Schaffer (1951) concluded that an arterial 
occlusion was associated with a significant decrease in the 
resistance of the associated collateral vascular bed. The 
decrease was metabolically based and was the consequence of 
the interaction among the increased APs, the vasospasm and the 
vascular tone of the region. Vasospasm was also observed by 
Awdeh (1978) in the principal nutrient vessel following an 
inflow occlusion. He believed this spasm was of vascular 
origin and was caused by the mechanical stimulation of the 
occlusion. 
Olsson et al. (1970) measured a three-fold increase in 
adenosine content of the blood in the ischemic tissue distal 
to obstruction and speculated that adenosine, a breakdown 
metabolite of ATP, played an important role in the recruit­
ment of collateral blood flow. An intimate relationship 
between distal tissue hypoxia and peripheral vascular 
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adenosine concentration was also reported by Berne et al. 
(1971) during their studies on the role of adenosine in 
peripheral vasodilatation. Berne, however, in his follow-
up studies in 1980, suggested that the adenosine released 
in response to an inflow occlusion was chiefly responsible 
for the collateral vascular recruitment. He observed that 
the adenosine level was closely correlated with the oxygen 
tension of the ischemic region. He believed that the 
adenosine-mediated maintenance of collateral blood flow was 
due to increased adenyl-cyclase activity resulting from 
increased adenosine contents in the tissue. Adenyl-cyclase 
increased c-AMP, which either reduced the cell permeability 
for calcium or blocked the calcium uptake by vascular smooth 
muscle cell. 
Edholm et al. (1951) compared blood flow in obstructed 
and unobstructed arteries of canine hind limbs. They found 
a significant increase in the blood flow to the obstructed and 
distally hypotensive hind limb, as compared to the unobstructed 
one. They postulated that this was due to a contralateral steal 
effect. Brkic and Laszt (1973), on the contrary, reported 
a significantly improved blood flow in the contralateral un­
obstructed hind limb of rats as compared to ipsilateral 
obstructed limbs. The increase in blood flow to the contra­
lateral unobstructed side can be attributed to the release 
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of vasodilatory agents and their subsequent transport to the 
contralateral limb, where they caused vasodilatation. A 
decrease in blood flow to the unexercised hind limb, as com­
pared to the exercised limb was observed by Kitamura et al. 
(1980). They believed this decrease was due to reflex vaso­
constriction in the unexercised limb, resulting from peripheral 
chemoreceptor stimulation. Thé accumulated metabolites, 
including PCOg, increased hydrogen ion concentration and 
lactate,were responsible for peripheral chemoreceptor reflex 
activity. 
Stenosis 
Mechanical stenosis of an arterial segment often is used 
to simulate an atherosclerotic obstruction in the experimental 
research laboratory. Partial stenosis, as opposëd to complete 
obstruction, has a complex influence on the blood flow 
through and beyond the narrowed segment and significantly 
alters the collateral and peripheral vascular hemodynamics. 
Since graded levels of stenosis of the principal nutrient 
vessel were produced in these studies, some of the significant 
effects of experimentally produced graded stenoses on col­
lateral and peripheral vasculature will be discussed. 
Gregg and Patterson (1980) reported that stenotic APs 
ranging between 6-9 mm Hg were required to recruit collateral 
blood flow. Pressure gradients of this magnitude were obtained 
11 
when the lumen diameter was reduced to 50 percent of its 
original diameter, a point at which flow through the stenosed 
artery was significantly reduced. Folts et al. (1973), 
however, found no significant reduction in blood flow through 
a stenotic segment with 10 mm Hg AP and 52 percent reduction 
in cross-sectional area. They did find a decrease in flow, 
however, when a lumen cross-sectional area was reduced by 
78 percent. This stenosis level was critical as it was 
associated with intravascular obstruction, endothelial cell 
damage, higher AP and lack of reactive hyperemic response fol­
lowing an occlusion. Similar findings were reported in 
the studies of Santamore et al. (1980), who showed that 
intravascular stenosis was associated with vasospasm, which 
enhanced the severity of the stenosis. They believed that 
the vasospasm was internally originated (potentiated) due 
to mechanical stimulation of the nerve endings in the vessel 
wall. 
Beckman et al. (1979) observed an inverse relationship 
between reactive hyperemic blood flow rate and peripheral 
vascular resistance which did not change noticeably until 
the stenosis c.s. area was reduced by 80 percent. There 
was significant decrease in blood flow at this level of 
stenosis and the release of stenosis caused a reactive 
hyperemic response. Similar findings were reported by 
12 
Kubicka et al. (1979) in an extracorporeal circulation. 
They observed that 98 percent reduction in c.s. area of the 
artery was the critical point where blood flow dropped to 25 
percent of its resting value. The flow, however, in their 
studies started to decrease when the lumen c.s. area was 
reduced by 75 percent. Sequential obstruction of potential 
collateral channels in these experiments did not signifi­
cantly alter the blood flow distal to the stenosis. 
Walinsky et al. (1979) defied the concept of fixed 
stenosis on the basis of his findings, which showed that the 
stenosis resistance was dynamic in nature and was influenced 
by a variety of factors. These included platelet aggrega­
tion, collateralization, turbulence and release of vaso­
active metabolites. These factors decreased R^, increased APS 
potentiated narrowing of the lumen by passive reverse stress-
relaxation mechanism and augmented the hemodynamic severity 
of the stenosis. Earlier, Roth et al. (1976), had proposed 
that the normal blood supply to the peripheral bed, even in 
the presence of moderately severe stenosis, was due to the 
interaction between collateral and peripheral vascular 
resistances. They had further proposed that during distal 
vasodilatation resulting from increased metabolic activity 
following an exercise, the distal pressure decreases and AP 
increases. This causes already existing moderate severe 
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stenosis in the system to become functionally more severe, 
which not only affects vascular collateralization but flow 
through the stenosis as well. Similar observations by 
Carew et al. (1968) were attributed to peripheral vaso­
dilatation and decreased intraluminal pressures distal to 
stenosis which lead to passive narrowing of the vessel 
lumen. 
May et al. (1963) observed an inverse relationship be­
tween the blood flow and AP with alterations in degree and 
severity of stenoses. There was direct correlation between 
the AP across the stenosis and its length, which however, did 
not change the hemodynamics in less than subcritical range. 
In the critical range, a 4 times increase in length of stenosis 
was associated with 25 percent greater reduction in flow 
through the stenosis. The findings of Feldman et al. (1979) 
showed that the critical level of a stenosis could be 
rèached at smaller decreases in c.s. area, with increase in 
stenosis length. A 75 percent stenosis over 15 ram length 
was as critical as a 96 percent stenosis over 1 mm length. 
Several stenoses in 'series in these studies produced an additive 
effect. Similar responses with stenoses in series also were 
reported by Gould and Lipscomb (1974) and Young (1979). Gould 
and Lipscomb. (1974), in addition, noticed that stenosis, greater 
than 85 percent, despite being associated with decreased 
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blood flow and flow reserve, did not change the resting blood 
flow distal to stenosis. Gould (1978), during his review of 
the functional aspects of a critical stenosis, suggested that 
percent decrease in c.s. area as a measure of stenosis 
severity was an unrealistic and oversimplified approach. 
This opinion was based on the observations that stenosis 
geometry and not the percent reduction in c.s. area 
alone altered pressures and flows. He mentioned that stenosis 
length, absolute diameter, divergence angles, eccentricity, 
turbulence and flow separation produce cumulative effects 
on the resistance, AP and flow reserve capacity in the region. 
Young and Tsai (1973) in in-vitro studies reported that 
flow separation resulting from stenosis significantly in­
fluenced the pressure and flow characteristics, which showed 
a nonlinear relationship at critical level of stenosis. They 
believed that the APs across the stenosis were dependent 
upon stenosis geometry, velocity of blood flow, inertial 
effects and viscosity of blood. 
Young (1979), however, reviewed the effects of stenosis 
and stenosis geometry on collateral and peripheral vascular 
bed hemodynamics and proposed that the performance of a stenosis 
be described as a function of peripheral and collateral con­
ductances and not simply by percent reduction in c.s. area. 
These observations were based on his own findings and findings 
of other researchers who had suggested that stenosis geometry 
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did not significantly influence vascular hemodynamics, except 
at moderate levels of stenosis. However, when peripheral 
resistance attains a minimal value, any increase in stenosis 
severity not only will decrease the blood flow further but 
will also influence the flow reserve in a significant manner. 
He suggested that stenosis resistance was not a fixed but 
a dynamic quantity which was influenced by collateral and 
peripheral vascular resistances. Similarly, Schwartz et al. 
(1980) reported that experimental or clinical stenosis was 
not a lesion with constant resistance. If it was, flow 
through a stenosis at worst would remain constant even if the 
oxygen demands of the distal ischemic bed increased markedly. 
But this is not usually the case, because dilatation of the 
peripheral arteriolar bed results in decreased arterial 
pressure beyond stenosis, which might cause a passive de­
crease in arterial caliber and intensify the severity of 
the stenosis. In previous studies (1979), they had 
shown that distal vasodilatation was associated with para­
doxical decrease in coronary blood flow, a concomitant 
increase in AP and an increase in stenosis resistance to a 
level five times that of the unoccluded vessel. It was be­
lieved that these effects could have occurred due to re­
lease of vasoactive metabolites distally in the peripheral 
bed following transient coronary artery occlusions. The 
vasoactive substances intensively dilate the distal vascular 
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bed and potentiate the hemodynamic severity of the stenosis. 
Prostaglandins 
PGs are synthesized by virtually every tissue in the 
body (Christ and Vandorp, 1972). Their release can be stimu­
lated by various means including hormones (bradykinin and 
angiotensin II), endogenous or exogenous neurotransmitters, 
tissue damage and decreased oxygen tension (Needleman et al., 1975a./, 
1975b, Needleman, 1976; Gunther and Cannon, 1980). Since there 
is no evidence that PGs can be stored, their release implies de-
novobiosynthesis (Piper and Vane, 1971). Little, if any, PGs can 
be detected in arterial blood because of efficient pulmonary 
destruction. Thus, PGs are considered as local hormones 
that are synthesized in response to different stimuli at or 
near their site of action. 
PGs are formed by the enzymatic oxidation of poly­
unsaturated fatty acids (AA) i.e., 8, 11, 14 ETEA (Di homo-
y-linolenic acid) and 5, 8, 11, 14 ETEA which form PGs of 1 
and 2 series, respectively. In the body, polyunsaturated 
fatty acids are not available in the free form but are 
bound to phospholipids and triglycerides. Therefore, PG 
synthesis can only follow the activation of lipases (phospho-
lipase Ag and possibly triglyceride lipase) which release 
bound fatty acids in free form. This free precursor of PGs 
(AA) is acted upon by cyclo-oxygenase with the incorporation 
of oxygen and results in the formation of PGGg and PGHg. 
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Aspirin and aspirin like drugs inhibit the biosynthesis of 
PGs by inactivating cyclo-oxygenase. AA also is converted 
by lipooxygenase in platelets to a noncyclized product 
HETE. 
Despite their own biological activity (vasoconstriction 
and platelet aggregation) PGGg and PGHg are very unstable 
intermediates and are very quickly (4-6 min.) converted to 
PGE, PGD and PGF series by isomerases and to TXAg by TXAg 
synthetase or by PG, 9 cyclase to PGIgt a potent platelet 
deaggregating agent. The generation of these PGs in dif­
ferent body tissues is dependent upon the type of stimuli 
and production of different synthetic enzymes. Enzymes 
require endoperoxide as a substrate and lead to the forma­
tion of different types of PGs (Needleman and Kaley, 1978). 
Since different PGs produce different effects (complementary 
and antagonistic), the ultimate response of an organ or a 
region to PG biosynthesis often represents the pathophysio­
logic condition of the vascular bed involved. 
The biosynthesis of PGs can be inhibited in vitro or 
in vivo by therapeutic doses of INDO (Flower, 1974). The 
dose level for inhibition of PG synthesis varies from species 
to species. For example, the guinea pig, as compared to the 
dog, requires 10-30 times more INDO concentration to effectively 
counter PG biosynthesis. In situations like this, very high 
doses of antagonists might be influencing other enzyme systems 
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in the body (Hamberg, 1972; Flower et al., 1972). 
The primary focus of this section is to review currently 
available evidence regarding the endogenous synthesis of 
PCs in different vascular regions and their regulatory role 
in the maintenance of tissue viability by modulating local 
vascular blood flow. 
Ali and McDonald (1977) observed that platelet incubation 
with AA caused biosynthesis of PGs within 2 minutes. The 
PGs synthesized were PGEg, PGFga, PGDg (stable forms) and 
PGGg, PGHg and TxAg (unstable forms). The PG biosynthesis 
was effectively inhibited by INDO pretreatment in lower 
concentrations. 
After studying the variable effects of PGs, Marmo 
et al. (1980) reported the direct, modulatory and reflex 
effects of PGIg, 6-Keto PGF^^ PGFg^ and 15(S)-15 methyl 
PGFg^ upon cardiovascular and pulmonary systems. PGIg 
produced a transient hypotension, venous vasoconstriction 
and reflex sinus tachycardia with marked reduction in 
baroreceptorial carotid sinus reactivity. PGFgO caused hyper­
tension, tachycardia, arterial and venous vasoconstriction, 
increased CO, cardiac stimulation,, increased sympathetic 
tone and changes in the excitability of barosensitive' zone 
of the carotid sinus. PGFg^ also increased respiration by 
peripheral bronchconstricter effect and was also associated 
with stimulation of respiratory center via chemoreceptors. 
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Messina et al. (1976) investigatdd the possible regu­
latory role of PGs in local circulation and proposed that 
PGs produced both vasopressor and depressor activity in 
different vascular beds. This activity varied from species 
to species. PGs of E and A series were always associated 
with weaker vasodilatory response, whereas other PGs produced 
variable effects. They suggested that despite these variable ef 
fects, PGs play a homeostatically significant role in control­
ling vasoreactivity of vascular regions. They are essential 
in the regulation of vascular tone and resistance and act 
independently without interaction with other vasoactive agents 
like serotonin, histamine and bradykinin. During similar 
studies. Dusting et al. (1977), noticed that PGE^ and TXAg 
opposed PGIg in the same vascular bed. PGEg, and PGHg 
produced transient vasoconstriction, whereas PGIg and AA 
completely relaxed isolated coronary artery strips. INDO 
and 15-HPAA increased the resting vascular tone and abolished 
AA induced relaxation of arterial strips. The inhibition of 
AA induced vasorelaxation by 15-HPAA suggested that AA caused 
vasodilatation via PGIg formation. 
Variable effects of PGs were also shown by Rose et al. 
(1974). AA caused hypotension, increased platelet aggregation 
and produced inconsistent effects on myocardial contractility. 
Aspirin completely abolished AA induced responses. PGEg 
and PGFgg, on the contrary, produced an immediate hypotension 
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and increased myocardial contractility, which remained 
unaffected by aspirin treatment. They suggested that AA 
induced responses were mediated by PGs (PGEg and PGFg^) or 
their intermediates (PGGg, PGHg). Similarly, in in-vitro 
studies on isolated coronary artery preparations, Kulkarni 
et al. (1976) observed that AA caused vasodilatation, whereas 
PGEg and PGEg^ produced vasoconstriction. PGE^ on the other 
hand, caused vasodilatation which was potentiated by INDO. 
INDO along with aspirin and meclofenamate inhibited AA 
induced vasodilatory responses suggesting that its actions 
were mediated by PGs. They postulated that PGE^, PGEg and 
PGFgg acted by inducing changes in vascular smooth muscle 
cyclic nucleotides (Schultz et al., 1973) and that PGEg and 
PGFgg induced vasoconstriction was due to increased c-GMP. 
PGE^ related vasodilatation may have been due to increased 
c-AMP concentration (Flores and Sharp, 1972). Hatano et al. 
(1980), while studying PG effects in different vascular 
tissues, showed that PGFgg was the most potent vasoconstric­
tive agent both in coronary and mesenteric arteries and 
PGIg was the most vasodilatory agent. PGE^ and PGEg pro­
duced feeble contractile activity in mesenteric arteries. 
The variable effects of differing PGs could be attributed 
to the presence of two different types of receptors which 
would have mediated the contraction and dilatation produced 
by PGs. 
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While investigating clinical implications of PGIg, 
Szczeklik et al. (1980) suggested that atherosclerosis was 
associated with disruption of PGIg in human lower extremi­
ties. PGIg infused intra-arterially or intravenously (5-10 
ng/Kg/72 hrs) improved blood flow and relieved all the 
symptoms associated with atherosclerosis including pain 
and ischemic ulcers. The improvement caused by PGIg in­
fusion was due to deaggregation of platelets in capillaries 
or due to proliferation of capillaries in the ischemic areas. 
Similarly, Ubatuba et al. (1979) reported that intravenous 
pretreatment with PGIg inhibited thrombus formation in 
carotid vessels with damaged endothelium. They suggested that 
PGIg-induced inhibition of thrombus formation was due to 
platelet deaggregation and increased c-AMP concentra­
tion. 
Moncada et al. (1976) postulated that the controlling 
factor in thrombus formation was the balance between TXAg and 
PGIg biosynthesis. TXA^ and PGI^ originate from common precursor 
endoperoxide (PGGg or PGHg). These substances possess 
their own vasoconstrictive properties (Hamberg et al., 
1975) and are responsible for platelet aggregation and 
ensuing release reaction (Hamberg et al., 1974). INDO in­
hibited PG biosynthesis by impairing transformation of PGGg 
or PGHg to TXA^ or PGIg and caused decrease in blood flow 
(Needleman et al., 1977a). This then may not only enhance 
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platelet aggregation and deposition but eventually may lead 
to thrombus formation in a blood vessel. 
Gunther and Cannon (1980) showed that temporary coronary 
occlusion was associated with increased PG synthesis in the 
ischemic areas of the myocardium. While investigating the 
assumed modification of angiotensin II activity by 
PGs, they noticed that administration of angiotensin II 
caused a marked increase in PG biosynthesis in isolated 
heart preparation. The response, however, was not pro­
nounced in in-vivo coronary vasculature. Angiotensin II also 
potentiated adrenergic activity and cardiac ionotropism by 
increasing catecholamine secretion. Pretreatment with INDO 
led to significant decrease in PG biosynthesis and increased 
vascular resistance suggesting that cardiac PG synthesis may 
have been regulating the coronary vasoconstrictor effects 
of angiotensin II. 
Folts et al. (1973) reported that 78 percent intra­
vascular stenosis significantly decreased blood pressure and 
flow across the stenosis and abolished reactive hyperemia 
response. The achievement of critical stenosis at a lower 
level of reduction in c.s. area was believed to be due to 
intravascular obstruction which caused vasospasm and altered 
the AP and blood flow across the stenosis. While investi­
gating the possible cause for myocardial infarction, they 
(1976) observed that 60-80 percent fixed stenoses were 
23 
associated with reductions In blood pressure and flow which 
returned cyclically back to control values following elimi­
nation of obstruction by physical poking or INDO treatment. 
On histologic examination, an amorphous mass of platelet 
aggregates was found in the narrowed lumen of the vessel. 
Platelet aggregation in the sténosed segment was due to 
platelet damage and activation by ADP. Later, Folts ét al. 
(1977) investigated the possible interaction of collateral and 
peripheral hemodynamics during vasospasm and subsequent cyclic 
reductions in pressure and flows during 60-80 percent fixed 
stenoses. Vasospasm in these studies was associated with 
distal bed ischemia (manifested by S-T segment depression) 
and platelet aggregation. Platelet aggregation disappeared 
following pinching or administration of aspirin. They 
suggested that collateral and peripheral hemodynamics were 
not involved in platelet deaggregation, which must have been 
due to some other mechanisms involved and/or due to increased 
AP across the stenosis. Folts and Beck during subsequent 
studies (1979), showed a regular and spontaneous disaggrega­
tion of blood platelets in coronary vessels with 70 percent 
stenosis. Cyclical reductions of pressure and flows lasted 
10-15 minutes. These events were potentiated by epinephrine 
and abolished by ibuprofen (a PG inhibitor). They suggested 
a possible role of epinephrine and PCs in the process of 
myocardial infarction. Vasodilator substances like 
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dipyridamole, nitroglycerine and papaverin inhibited the 
cyclic reductions of pressure and flow. 
Folts and Rowe (1980), however, observed the disap­
pearance of these oscillations with aspirin, ibuprofen, sulfa-
pyrazone treatments and mechanical intervention (physical 
poking or pinching). By these results, they substantiated 
the previous findings that platelet aggregates were responsible 
for reductions in pressure and flow in coronary, carotid 
and femoral arteries. They proposed that the resulting 
vasospasm and platelet aggregation following an arterial 
occlusion was due to release of vasoactive PCs and not due 
to mechanical stimulation of the nerve endings in the 
arterial wall. In contrast, Uchida et al. (1980) suggested 
that the cyclic reductions of blood pressure and flow in the 
partially constricted coronary arteries were the consequence 
of vascular spasm and not platelet aggregation or thrombus 
formation. These suggestions were based on their studies 
with angiography and microscopy. During angiographic studies, 
they observed the downstream narrowing, accompanying a coro­
nary stenosis, to be of uniform, smooth and symmetrical 
diameter which was uncharacteristic of platelet aggregation 
or thrombus formation. On microscopic examination they found 
no evidence of platelet aggregation. The disappearance of 
vasospasm with vasodilatory drugs like dipyridamole. 
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nitroglycerin and papaverin reinforced their previous obser­
vations in these studies. The researchers suspected that 
vasospasm was responsible for the cyclic reductions in 
pressure and flow. The vasospasm, they further suggested, 
was of vascular origin and was eliminated by nonspecific 
vasodilatory substances. During their preceding studies 
(1977a, 1977b, 1978a, 1978b), however, they had shown 
that reductions in pressure and flow in a partially stenosed 
coronary artery were abolished by aspirin, phenylbutazone, 
benzydamine, cu-chlorophylline and PGIg. The reductions on 
the other hand were potentiated by epinephrine, PGE2, lack of 
glutathione and 15-HPAA with inconsistent presence of platelet 
aggregation in the stenosed vessel. During these studies, Uchida 
et al. (1978b) had suspected the possible role of PGs, plate­
let aggregates or vasospasm in cyclic reductions of pressure 
and flow following partial occlusion. 
While supporting the findings of Folts et al. (1977), 
Capurro et al. (1979) observed that cyclic reductions in 
coronary blood flow were due to platelet aggregates and PG 
biosynthesis. Aspirin induced improvement in flow was due 
to direct effect of aspirin on platelet aggregation and not 
to PG biosynthesis. Helenski et al. (1980), however, showed 
that thrombosis induced vasospasm was due to platelet activa-
A 
tion, and simultaneous release of SRT and TXAg, which not only 
directly affected the thrombosed artery but may have caused 
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vasospasm in the collateral vessels as well. Pretreatment 
with INDO relieved the vasospasm and improved Q^. They sug­
gested that INDO acted principally by inhibiting the bio­
synthesis of TXA2 rather than of all other PCs and that SRT 
in some way was related to TXAg release. Release relation­
ship between TXA^ and SRT also was suggested by O'Donnel 
and Fiedel (1979). 
Capurro et al. (1980) revealed that aspirin not only 
caused platelet aggregation in coronary arteries but also 
abolished AA induced vasodilatation in these vessels. Plate­
let aggregation potentiated by low doses of aspirin was in­
hibited at higher doses. PGIg induced vasodilatation was 
unaffected by aspirin. This was because aspirin inhibited 
the biosynthesis of PCs at the eyelo-oxygénase level, hence 
exogenous PGIg response was unaffected, whereas AA induced 
vasodilatory response was abolished. They suggested that AA 
induced vasodilatation was mediated by PGs, possibly PGIg. 
During subsequent studies Capurro et al. (1981) found that aspirin 
pretreated animals responded more effectively to.exogenous 
PGIg than those that were not treated. PGIg significantly 
improved blood flow to the myocardium following aspirin pre­
treatment. The response to adenosine, nitroglycerin and 
nitroprusside compounds, however, did not change with 
aspirin pretreatment. They postulated that improvement in 
blood flow following aspirin pretreatment could have been due 
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to its inhibitory effect on biosynthesis of PGs. These in­
hibited PGs could have included those with direct vaso­
constriction effect and also those that might mediate their 
vasoconstrictive effects by release of catecholamines. 
Jugdutt et al. (1979), while determining the role of 
PGs in myocardial infarction, observed that INDO potentiated 
infarction following coronary artery occlusion. This was 
due either to reduction in PGEg mediated increase in coronary 
blood flow or to unopposed vasoconstrictive effects of PGGg, 
PGHg and TXS. They suggested, however, that the exact 
mechanism of INDO action was not clear and was yet to be 
elucidated. Similar findings were reported by O'Beaty and 
Donald (1979) in the canine hind limb. They contended that 
PGs were responsible for maintaining hind limb blood flow 
following inflow occlusion during rest and exercising states. 
The inhibition of PGs by INDO and meclofenamate increased 
vascular resistance and decreased blood flow under resting con­
ditions. This decrease in blood flow was due to a nonspecific 
vasoconstrictive action of the inhibitory agent on the vascula­
ture following an inflow occlusion. Alexandar et al. (1975), how­
ever, suggested that INDO induced decrease in RH at all levels of 
occlusion was due to inhibition of PGE^. They believed that 
PGE^ was the prime regulatory factor of blood flow during' 
myocardial ischemia (Alexandar et al., 1973). The ischemia 
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of very short duration (less than a minute) may not have 
been associated with PCs release. Therefore, blood flow 
under these very acute situations must be regulated by 
substances other than PGs. PCs, however, do control blood 
flow regulation during longer durations of arterial 
occlusions (Needleman and Kaley, 1978). 
Serneri et al. (1980) investigated the effects of 
ischemia produced by 3 minutes of arterial occlusion and 15 
minutes of venous stasis, on the production of PGIg. They 
found that PGIg was produced during the first minute of RH 
and declined subsequently with repeated episodes of inter­
mittent ischemia. Despite similar observations during 
venous stasis, PGIg generation was three times less than 
arterial occlusion. Similar findings were reported by 
McGiff and Itskovitz (1973) on kidneys and Block et al. (1975) 
and Moncada et al. (1977a) in rabbit hearts. They believed 
that local blood flow changes due to arterial occlusion in­
duce PGIg release which maintains blood supply to the 
ischemic region. INDO in these studies inhibited the syn­
thesis of PGIg. PGs played a regulatory role in the 
maintenance of blood flow, following an arterial occlusion, 
in the preparations of Owen et al. (1975) . Decreased blood 
flow observed in these preparations following INDO treatment 
could have been due to: i) inhibition of normal PG bio­
synthesis, ii) inhibition of enhanced PG biosynthesis, or 
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iii) nonspecific vasoconstrictor effect of INDO on vascular 
smooth muscle. INDO action directly on platelet aggregation 
and indirectly in the modulation of neural tone was also 
speculated in these studies to be a possible cause of de­
creased blood flow in the region. 
Rosenblxim et al. (1980) reported that the cyclo^oxygenase 
inhibitors, aspirin and INDO enhanced platelet aggregation 
in mesenteric vessels. Mesenteric vessels normally produce 
PGIg, which is a platelet deaggregating agent. Aspirin and 
INDO induced platelet aggregation was possibly dUe to in­
hibition of PGIg synthesis, which might have been regulating 
the microvasculature reactivity and tissue viability. Con­
trary to those studies, Glenn and Horan (1981) observed an 
adenosine mediated increase in coronary blood flow in 
ischemic myocardium following INDO treatment. They suggested 
that INDO potentiated increased blood flow may have been due 
to inhibition of vasoconstrictor PGs which were predominantly 
released during an inflow occlusion. 
Flower (1974), while investigating the mechanism of INDO 
action, found that it acts in the early stages of PG syn­
thetic pathway in a competitive irreversible fashion. INDO 
exerts its effect by combining slowly with the active site 
and decreasing the catalytic activity of the enzyme in a time 
dependent manner. The long lasting effects (24-48 hrs) 
following oral administration are due to its conversion to 
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active metabolite. 
Moncada et al. (1977b) reported that imidazole inhibited 
the enzymic conversion of PGGg or PGHg to TXAg by platelet 
microsomes without affecting PGIg biosynthesis. Imidazole 
induced TXA2 inhibition was complete and selective in nature 
(Needleman et al., 1977b). The studies of Busse and Seuter 
(1969), however, revealed incomplete inhibition of TXAg fol­
lowing methyl imidazole treatment of aggregated platelets. 
PGE^ and PGIg, on the other hand, not only deaggregated the 
platelets but also blocked TXAg and melonaldehyde production 
by elevating intracellular c-AMP concentration. Despite 
their role in platelet aggregation adenosine, ATP and AMP 
did not affect TXAg or melonaldehyde production. AA adminis­
tration in their studies caused rabbit mortality, which was 
effectively blocked by INDO, aspirin and methyl imidazole 
treatment. On the basis of these observations, they sug­
gested that pharmacological inhibition of platelet function 
could not be achieved by a uniform mechanism controlled by the 
AA pathway. 
Serotonin 
Coronary artery disease, complete occlusion and critical 
stenoses are associated with platelet aggregation (Haerem, 
1972; Folts et al., 1973; Coe and Salzman, 1976; Uchida 
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and Murao, 1979). Interaction between platelets and damaged 
endothelium may lead to thrombus formation (Danese and 
Haimov, 1971; Horie et al., 1978). The aggregated plate­
lets and thrombi formed, in addition to ischemic tissue, 
release a variety of vasoactive substances including 
SRT (Bulle,. 1957; Gladkova and Vasiliev, 1971; Kordenat and 
Kezdi, 1979). SRT has been implicated in producing vari­
able effects in different vascular beds, depending upon the 
number and type of receptors present and existing tone of the 
vascular bed (Dalessio, 1972) . 
Page and McCubbin (1953) examined the amphibaric action 
of SRT on vascular smooth muscle. When the neural tone was 
normal or increased, SHT behaved as a vasodilator. When 
the vascular tone was low, it acted as a powerful vaso­
constrictor agent. Similarly, Haddy (1960) observed 
that SRT actively constricted larger blood vessels and dilated 
smaller ones. It lowered the systemic blood pressure in 
hypertensive animals and increased blood pressure in hypo­
tensive animals. Pillion et al. (1971) reported cardiac 
stimulation in response to SRT administration in addition to 
the responses observed by Haddy (1960). 
Bock et al. (1957) and Glover et al. (1958) noticed an 
increase in forearm and muscle blood flow with simultaneous 
decrease in skin blood flow following SRT administration. 
While comparing SRT and epinephrine effects on isolated 
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cerebral arteries, Toda and Fugita (1973) found that SRT 
induced contractions were more pronounced than epinephrine. 
The response was of reverse nature in mesenteric vessels. 
The researchers thought this response was due to transition 
in SRT receptor distribution from higher to lower 
vessels. The findings of Urthaler et al. (1980), however, 
showed significant vasoconstrictive effect of SRT on renal 
and mesenteric vessels. The SRT effects were not pronounced 
on coronary, carotid and femoral vessels. No change in 
forearm blood flow, following continuous intraarterial or 
intravenous infusion of SRT was observed by Daugherty et al. 
(1968). They speculated that the route of administration 
played no role in SRT actions. Zucker and Cornish (1980), in 
their studies, observed hypotension and bradycardia followed 
by delayed tachycardia and hypertension, following a single 
bolus injection of SRT. They suggested that SRT administered 
intraventrieally invoked a hypertensive coronary chemoreflex. 
Daicoff et al. (1968) and Swedenborj (1971) found that 
experimentally induced stenosis was associated with SRT 
release, which caused pulmonary vasoconstriction. Pretreat-
ment with methysergide blocked the SRT induced vasoconstric­
tion. They believed that methysergide acted peripherally and 
locally with a nonperceptible effect on CNS. 
Lewis and Reichert (1926) reported that femoral artery 
thrombosis was associated with severe pain and ulceration of 
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the heel, which led to an asymptotic condition. Surgical 
removal of thrombus not only restored blood flow through the 
stenosis but also across the collateral vascular bed. During 
similar studies, Imhoff (1961) observed that the acute liga­
tion of feline distal aorta produced only transient ab­
normalities, whereas ligation associated with blood clot 
caused paralysis, loss of femoral pulse and cold extremities. 
Aortograms obtained during Imhoff's studies showed the . 
presence of collateral blood flow following an acute ligation 
which was significantly reduced in clot associated ligated 
animals. He believed that release of some vasoactive agents 
from the blood clot depressed the collateral blood flow. 
Sullenberger et al. (1959) found a severe depression of 
blood flow in the microvasculature of the ischemic tissue 
distal to occlusion. They attributed this depression in 
flow to the release of SRT from venous thrombosis. The re­
lease of SRT with strong vasoconstrictive properties following 
coronary artery ligation was also reported by Gladkova and 
Vasiliev (1971). 
Schaub et al. (1976) investigated the role of thrombosis 
in the regulation of collateral blood flow in the feline hind 
limb. They showed that thrombotic limbs did not carry sub­
stantial quantities of collateral blood flow which they 
suspected was due to ADP and SRT release. SRT in addition, 
increased capillary permeability, caused endothelial cell 
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damage (Majno et al., 1967) and damaged collateral vessels 
rendering them nonfunctional. During follow-up studies, 
Schaub and his associates (1977b), compared the endog-
enously released SRT actions with those that were exogenously 
administered. Exogenous SRT (6 yg) in a closed aortic segment 
caused decrease in hind limb blood flow, which was abolished 
in cinencerin hydrochloride pretreated animals. Similar 
results were obtained when animals were pretreated with RZP 
and/or PCPA. These drugs decreased SRT levels and exhibited 
recovery in collateral blood flow. These observations sug­
gested the possible role of SRT during thrombosis in the regu­
lation of collateral blood flow (Schaub et al., 1977b). During 
identical studies in the coronary arteries, Kordenat and 
Kezdi (1979) improved collateral blood flow with METH in 
thrombus associated coronary myocardium. 
Bell et al. (1967), Zarvas et al. (1971), Welch et al. 
(1973) and Reuse-Blom (1976) showed that endogenously re­
leased SRT following an acute ligation was responsible for a 
vascular spasm that lasted several hours and caused severe 
reduction in blood supply to the ischemic tissue. Similar 
vasospasm characterized by a pronounced vasoconstriction 
was also reported by Hellstrom (1979). It potentiated the 
myocardial ischemia, caused endothelial cell damage, produced 
vascular stasis and augmented thrombus formation in already 
sclerotic vessels. He suspected these responses were due to 
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release of vasoactive substances from the ischemic tissue. 
METH is a potent SRT antagonist and has been frequently 
used to block SRT in various body tissues (Halpern et al., 
1960; Owen et al., 1971). It competes for SRT uptake at the 
receptor sité (Curran et al., 1967). 
While investigating the METH actions in different vascu­
lar regions, Saxena (1974) observed a selective vasoconstric­
tion in the carotid artery vascular bed following METH 
treatment. Femoral, superior mesenteric, renal and vertebral 
artery vascular beds were, however, not affected even in 
larger doses. This was due to quantitative variation 
in both type, population and sensitivity of receptors 
subserving METH induced peripheral vasoconstriction (Dalessio, 
1972; Saxena, 1972). In contrast, Graham (1964) reported 
that METH was associated with arterial spasm in the hind 
limb, cramps in the lower legs and swelling of the feet in 
human beings. Similarly, Dalessio et al. (1961) and Curran 
et al. (1965) noticed a bilateral lower extremity vascular 
spasm following oral doses of METH. Saxena (1972), however, 
suggested that the net effect of METH in a vascular bed 
depended upon its pre-existing vascular tone. It causes 
vasoconstriction in a vascular bed with low vasomotor 
tone and vice versa. 
Koe and Weissman (1966) investigated the effects of PCPA, 
a SRT blocking agent, and reported that PCPA was the selective 
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depletor of SRT in the brain as well as peripheral nerves and 
did not affect catecholamines, MAO and tryptophan decarboxy­
lase in the body tissues. Bloom and Giarman (1968) described 
PCPA as specific inhibitor of tryptophan hydroxylase, a rate 
limiting enzymes in the synthesis of SRT. The longer dura­
tion of PCPA induced SRT depletion was due to the conversion 
of PCPA to an active metabolite, PCPA pyruvic acid, which 
caused irreversible conversion of tryptophan hydroxylase. 
RZP, another depletor of SRT from platelets and body 
tissues, was studied by Carlsson et al. (1957) . They suggested 
that the exact mechanism of RZP induced SRT depletion was 
not known. They believed RZP acted by simple displacement 
of SRT at the receptor site and destroyed the binding capa­
bility of the receptor for SRT by denaturing the storage site. 
They proposed a possible reserpine effect in the inhibition 
of the transport system and the storage of the granules. 
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MATERIAL AND METHODS 
Experimental Model 
The canine hindleg was selected to serve as a regional 
blood flow model of a main vessel-collateral arterial system. 
The arteries of the hindleg are easily accessible for instru-
mentation. A mechanical stenosis was used to simulate an 
obstruction to flow as might be found in the femoral arterial 
thrombosis. By this means, a model of arterial obstructive 
disease is developed. The DFA, the PCPA, the CGA and the 
SA including the muscular and the DCIA branches are the 
chief inputs of collateral blood supply to a peripheral bed, 
the hindleg below the stifle joint. The DCFA, another col­
lateral artery, emerges from the femoral artery in the distal 
thigh region. It gives off branches to the tissues both 
above and below the stifle joint (Fig. 1). In the resting 
state, the AP is such that it normally carries blood from the 
femoral artery in a reverse direction (centrifugal) into the 
thigh region (collateral bed). Blood flow supplied into the 
thigh via DCFA (henceforth referred to as nutritional blood 
flow) is to meet nutritional requirements of the caudal por­
tions of the thigh musculature and hamstring muscle group 
distal to the stifle joint. During an obstruction, when flow 
in the femoral artery is substantially reduced, the AP re­
verses and the DCFA receive blood from the descending branches 
of the cranially located thigh arteries and provides collateral 
Figure 1. The chief arteries and some of the potential 
collateral vessels in the hind limb of the 
dog (reproduced from Anatomy of the Dog 
by Miller et al., 1979) 
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blood flow to the peripheral bed (henceforth referred to as 
collateral blood flow). The direction of collateral blood 
flow in DCFA is centripetal with respect to the femoral 
artery. The volume of flow carried by the DCFA has not been 
studied. In this study, therefore, an attempt was made to 
quantify the volume of DCFA flow under normal and obstructed 
flow conditions. 
Hemodynamic Measurements 
Blood flow measurement 
Morphological and tracerdye studies of the dog have shown 
that the femoral artery supplies blood to the hind leg and 
the femoral vein returns all the peripheral blood from the 
hind leg distal to the proximal caudal femoral vein. During 
partial or complete femoral artery occlusion, blood is 
supplied to the ischemic lower hind leg peripheral bed by the 
collateral vessels in the thigh region. The flow through 
the femoral artery (Q_) and its corresponding vein, the femoral 
(Q ) was measured by two 3 mm id. cannulating EMF transducers 
P 
(Biotronix, BLG GlO Electromagnetic flowmeter, Biotronix 
Lab. Inc., Riversprings, Md). To determine the volume of 
flow accurately, these flow transducers were calibrated by 
the method of Young et al. (1975) at the end of each experi­
ment (see Appendix A). Collateral blood flow was estimated 
as the difference between Q_ and Q . p s 
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Blood pressure measurement 
Blood pressures were measured at 5 different locations 
in the hind limb by Statham Model P23Ac transducers 
(Statham Medical Instruments, Inc., Hato Rey, Puerto Rico) 
(Lambert and Wood, 1947). All of the transducers were mounted 
at the same elevation as the hind leg. They were calibrated 
with known pressures before the start of the experiment (see 
Appendix A). Site selection for each pressure measurement 
was based on its potential role in collateral and peripheral 
hemodynamics. The pressures measured were as follows: 
Pa: Mean arterial blood pressure at the level of 
abdominal aorta, very close to the origin of 
common iliac artery and just above the region 
where several arteries branch and contribute to 
the hind limb collateral vascular bed (collateral 
circulation driving pressure). 
Pj^: Mean arterial blood pressure in the femoral artery 
proximal to stenosis (driving pressure for flow 
through stenosis). 
P^: Mean arterial blood pressure in the femoral artery 
distal to stenosis. 
Pg: Mean arterial blood pressure in a branch at the 
DCPA level (potential collateral blood pressure). 
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PV: Mean arterial blood pressure at the femoral vein 
upstream from the flow transducer (venous blood 
pressure). 
The following equations were used to calculate the R_, 
and Rp. 
Dimensions of these variables are; 
P (Pressure) = ram Hg 
Q (Flow) = ml.sec ^ 
R (Resistance = mm Hg.sec.ml ^ 
The schematic representation of the experimental model 
showing the distinctive sites of pressure and flow measure­
ments is shown in Fig. 2. 
Preparation of the Experimental Animal 
Anesthesia 
The experiments were performed on 28 mongrel dogs of 
both sexes weighing 22 to 36 Kg. The animals were lightly 
anesthetized with thiamyl sodium (Surital, Parke-Davis and Co., 
Detroit, MI.) 30 mg/Kg iv, and were cannulated with an endo­
tracheal tube to facilitate proper ventilation. During the 
Figure 2. Schematic representation of hind limb of the dog 
with various resistive vascular components and 
sites of pressure and flow measurements 
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course of the experiment, the animals were maintained in the 
surgical plane of anesthesia with a-chloralose (Sigma, St. 
Louis, MO.) 25 mg/Kg iv, as and when required. Body tempera­
ture was maintained constant with heating pads and was 
monitored on YSI telethermometer (Yellowsprings Instrument 
Co., Yellow Springs, Ohio). The EKG was monitored with a 
Corbin-Farnsworth LIFE GUARD device (Gould Inc., Instrument 
Systems Division, Cleveland, Ohio). A constant infusion 
(3.5 ml/Min iv) of dextrose 5 percent in bicarbonated lactate 
Ringer solution was given to maintain fluid balance during the 
experimental period. 
Surgical procedure 
To expose the femoral artery for the emplacement of an 
instrumented bypass device, an incision was made between MCFA 
and DCFA on the medial aspect of the left thigh. The 
sartorius and semimembraneous muscles were dissected at their 
insertions and the medial fabella, located adjacent to the 
condyle of the femur, was removed. The femoral artery and 
the corresponding vein were exposed and isolated in the 
region between the MCFA and the DCFA (Plate 1). 
A second incision was made at the PCFA level in the 
contralateral limb and the PCFA was isolated. Cautery was 
used during the surgical procedure to minimize hemorrhage 
from the exposed tissues following administration of heparin. 
Plate 1. The surgical Incision on the medial aspect of 
the thigh between MCFA and DCFA. 
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a - Femoral vein 
b T Femoral artery 
c - DCFA 
d T.. HCFA 
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At this point, the animal was given heparin (3 mg/Kg iv) 
Heparin at half this initial dose was repeated at hourly 
intervals in order to avoid clotting problems during hemo­
dynamic measurements. 
Cannulation 
A branch of the DCFA was cannulated to record P^. This 
procedure was followed by cannulation of the contralateral 
PCFA to record Pa. The cannula in PCFA was advanced into the 
abdominal aorta to a point very close to the origin of the 
common iliac artery. At this stage, the femoral arterial and 
venous segments were cannulated (Plate 2) with a specially 
designed extracorporeal perfusion apparatus consisting of 
the two bypass circuits, one for the femoral artery and one 
for the corresponding femoral vein (Plate 3). The decision 
to use extracorporeal bypass systems was made; i) to avoid 
the loss of potential collateral vessels for measuring blood 
pressures and ii) to avoid the artifacts due to closeness 
of the hemodynamic measuring devices which would have made 
estimation of pressures and flows difficult. 
Arterial Bypass System 
The arterial bypass system was composed of two pressure 
taps proximal (P^) and distal (Pg) to a stenotic segment (R^) 
Plate 2. Femoral artery and femoral vein cannulated with 
extracorporeal bypass circuits. 
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a - Femoral artery 
b - Femoral vein 
c - Infusion tap 
Plate 3. Extracorporeal bypasses for artery (a) and vein 
(b) are shown 
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a 3 mm id EMF transducer (Q^) with large diameter (greater 
than femoral artery diameter, medical grade silicone 
rubber tubing at both ends which led to the cannulas. 
Venous Bypass System 
The venous bypass included a pressure tap (P^) and KCl 
coated silver reference electrode proximal to EMF transducer 
(Qp) and a platinum hydrogen electrode distal to the flow 
probe with medical grade silicone rubber tubing at both ends. 
The total length of the tubing including connectors and EMF 
transducers was 76 cms in each bypass. 
Flow and Resistances in the 
Bypass Circuits 
To determine the flow resistive effects of these by­
passes, an experiment was performed. The fluid dynamics of 
each extracorporeal bypass was examined under a constant 
pressure head and varying flow conditions. The data thus ob­
tained are presented in Appendix B (Tables B1-B3). According 
to these data, flow in 1-2.5 ml/sec range was laminar. This 
flow rate did not significantly change the fluid dynamics in 
the bypass. However, when flow rate increased beyond 3 ml/sec, 
turbulence occurred and resistance increased to 1.99 and 1.04 
mm Hg*sec«ml~ in the arterial and venous bypass, respectively 
(Appendix B, Fig. Bl). The bypass circuit flow resistance at 0% 
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stenosis thus was almost insignificant compared to that meas­
ured with a critical stenosis applied (Appendix B, Fig." B2). 
In the arterial segment, the higher initial resistance at 
the lowest flow rate could not be explained. It may have 
been due to a small pressure differential across the 
arterial segment which may not have been accurately detected 
by the pressure transducers. On the basis of these observa­
tions it was concluded that bypass systems did not signifi­
cantly affect the in vivo hemodynamics. 
The pressure taps P^ and P^ in the extracorporeal 
bypasses, along with catheters from the P^ and Pg were then 
connected to their corresponding transducers. All the 
transducers were mounted at the same elevation. Standard 
cardiac catheters (id = 1.42 mm and od = 2.33 mm) were used 
for all pressure measurements except P^, for which a 
polyethylene catheter P.E. 50 (id = 0.76 mm, od = 1.22 mm) 
was used. 
Instrumentation 
Pressures and flows were recorded on a Grass model 7 
polygraph (Grass Instrument Co., Quincy, Mass.). Outputs 
from the polygraph were simultaneously being recorded as a 
raw (analog) data on a 7 channel instrumentation tape 
recorder/reproducer (Honeywell model 5600, Honeywell Test 
55 
Instruments Division, Denver, CO.) and Laboratory Digital 
Computer (Pdp 8e, Digital Equipment Corporation, Maryland, 
Mass.) for instantaneous analysis of the analog data 
(analog to digital conversion). The digitized signal 
was stored on storage oscilloscope monitor over 12 sec 
periods and included 256 sampling points. Signals that 
lasted for a minimum of 4 seconds were instantaneously 
analyzed and averaged each time for digital output. The 
analyzed signals included 6-10 pressure and flow waveforms 
(approximately 80-85 sampling points) depending upon the 
heart rate of the animal. This was done in an effort to 
get representative and reliable data (complete set-up of 
data acquisition equipment is schematically shown in 
Fig. 3). 
Experimental Design 
Endothelial cell damage, platelet aggregation and distal 
ischemia are all associated with partial or complete arterial 
occlusions. They trigger a biochemical sequence of events 
which eventually leads to the release of vasoactive substances 
including PCs, TXs and SRT (Fig. 4). In this study an attempt 
was made to identify and characterize the regulatory role of 
these compounds by observing the influence of their 
respective antagonists at 6 levels of progressive stenosis 
(0, 60, 80, 90, 95 and 100 percent reduction in flow c.s. area 
Computer 
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Figure 3. Schematic representation of data acquisition equipment used during 
pressure and flow measurements 
57 
Critical Stenosis/Occlusion 
I , 
—— Ischemia « — i fl 
T 
Platelet Aggregation -^HC State -•THRO 
I 
ADP —- Release of Subst. *- 5HTy Rec. site 
1 1  /  I  \  
Xënthfn» cAMP 1 RZP METH PCPA 
Cell Phospholipid 
Phosphollpase A2 
Arachldonic Acid 
-Cyclo oxygenase 
PGEg 
PG Synthetase 
Endoperoxldes 
PGH2 
PG synthetase f 
PGF2 *< ' L. 
PGI2 synthetase. 
TX-synthetase 
T 
Imldazoh 
• 15-HPAA 
TXA2 
I 
TXB2 MDA 
PGI2 
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in the femoral artery). SRT was antagonized at the receptor 
site with METH (Curran et al., 1967; Saxena, 1974) or RZP 
(Carlsson et al., 1957; Shore et al., 1955; Shore, 1962) 
and at the neuronal level by PCPA and RZP (Koe and Weissman, 
1966; Bloom and Giarman, 1968). 
The synthesis of PCs and TXs were inhibited at the 
cyclo-oxygenase level by INDO (Flower, 1974; Moncada 
et al., 1976; Rosenblum et al., 1980). TXA2 was specifically 
blocked at the thromboxane synthetase level by IMZ (Hamberg 
et al., 1975; Moncada et al., 1977b). 
The 28 animals were divided into 6 groups. Each group 
received either an agonist or antagonist drug or both fol­
lowing measurements of hemodynamic variables under resting, 
untreated conditions. Gl, G3, and G4, each received ACH 
and SRT as agonists, whereas G2 received only SRT as agonist. 
G2 to G6, were all subjected to various antagonist treat­
ments, i.e., METH, PCPA, R + PCPA, INDO and IMZ, respectively. 
Pressures and flows were measured at 6 graded levels of 
stenosis during the C, ACH, METH, INDO and IMZ treatments in 
various groups (Table 1), whereas during SRT, PCPA and R+PCPA 
the pressures and flows were measured at 0, 95,and 100 percent 
stenosis levels. 
All the 8 animals in Gl were subjected to DCFA occlusion 
to test; i) the hypothesis that this vessel serves as the 
Table 1. Experimental design showing groups, treatments, and number of animals in each treatment 
Groups Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
Treatments^ C ACH SRT C METH SRT PCPA ACH SRT R+PCPA ACH SRT C INDO C IMZ 
4 4 4 
4 4 4 
4 4 4 
4 4 
4 4 
^ACH - (1-2 g/Kg/Min ia) 
SRT - (15-30 ug/Kg/Min ia) 
METH - (100 yg/Kg iv 30 minutes prior to measurements) 
PCPA - (300 mg/Kg orally every 72 hrs prior to e^^eriment) 
R or RZP - (5 mg/Kg orally 8-10 days before the e^^eriment) 
INDO - (20 mg/Kg orally 1-2 hrs prior to measurements) 
IMZ - (10 yg/Kg iv 1/2-1 hr prior to measurements). 
^Numbers in treatment column represent the number of animals subjected to a treatment. 
^Variation in the number of animals subjected to each treatment within a given group was either 
due to fewer animals treated or to rejection of data deemed unreliable because it was obtained late 
in a long experimental period. 
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principal collateral recipient vessel (Plate 4), and ii) to 
quantify the nutritional blood flow supplied by this vessel 
to the thigh musculature. The DCFA receives nutritional 
blood flow from the femoral artery under normal flow condi­
tions. ACH was administered in 5 of these animals and blood 
flow was measured before and after DCFA occusion at 0, 95 
and 100 percent stenosis levels. 
Blood samples were obtained for analysis of SRT concen­
tration at 0/ 95 and 100 percent stenoses from animals in Gl, 
G2, G3 and G4. SRT concentration was determined by the spectro-
photo-fluorometric assay procedure of Maickel et al. (1968). 
The principal steps in this procedure originally were adapted 
by Bogdanski et al. (1956) and were subsequently modified by 
Waalkes (1959). An assay kit (Regis Chemical Co., Morton 
Grove, Illinois) based on the Maickel et al. (1968) method was 
used for SRT analysis (the stepwise analytical procedure for 
SRT determination is shown in Appendix C). 
Data Analysis 
All of the data obtained were tabulated. Statistical 
analysis included nested split, split plot experimental 
design using a model incorporating a multivariate two way 
classification with unequal number of observations and paired 
student "t" test (Snedecor and Cochran, 1976). 
Plate 4. Femoral artery (a) and corresponding vein (b) 
are isolated with DCFA (c) and MCFA (d) 
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RESULTS AND DISCUSSION 
The objective of the present investigation was to deter­
mine the influence of endogenously released vasoactive 
substances on collateral and peripheral hemodynamics during 
graded arterial stenoses. Pressures and measured flows were 
utilized to calculate the hemodynamics in the region. The 
values thus determined are presented in Fig. 5 to Fig. 22 
and Table 2 through Table 9. 
QQ (Fig. 5) in resting, untreated animals did not change 
significantly until a 95 percent decrease in c.s. area was 
reached. R (Fig. 6) and R^ (Fig. 7), however, remained 
c P 
unchanged during this period, suggesting that maximum vaso­
dilatation of both vascular beds had occurred before the 
experiment was started. R^ (Fig. 8) increased with each 
grade of stenosis but attained significance only at 95 per­
cent decrease in c.s. area. Contrary to this, a 90 percent 
stenosis caused a significant increase in R^ under elevated 
flow conditions (Fig. 8). R^ (Fig. 7) dropped markedly at 
all levels of stenosis, whereas (Fig. 5) and R^ (Fig. 6) 
remained unchanged throughout the experiment. 
The above observations are identical to those reported 
by Roth et al. (1976) and Walinsky et al. (1979), who sug­
gested a limited role of collateralization during distal 
vasodilatation, despite decrease in blood flow through the 
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Figure 5. Collateral blood flow during graded levels of 
femoral artery stenosis before and after acetyl­
choline infusion in the peripheral vascular bed 
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Figure 6. Collateral vascular resistance during graded 
levels of femoral artery stenosis before and 
after acetylcholine infusion in the peripheral 
vascular bed 
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Figure 7. Peripheral vascular resistance during graded levels 
of femoral artery stenosis before and after 
acetylcholine infusion in the peripheral vascular 
bed 
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Figure 8. Femoral artery resistance during graded levels of 
stenosis before and after acetylcholine infusion 
in the peripheral vascular bed 
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stenosis due to vasoplasticity. Distal vasodilatation caused 
by drug infusion, ischemia or hypoxia is associated with a 
decrease in pressure and resistance distal to stenosis with 
simultaneous increase in R . This increase leads to po-
tentiation of the hemodynamic severity of the stenosed seg­
ment (Young et al., 1977; Schwartz et al., 1979, 1980). 
The decrease in during distal vasodilatation is believed 
to be due to passive narrowing, which occurs immediately 
downstream from the stenosis. Distal dilatation causes 
increase in AP across the stenosis by lowering distal pressure. 
f 
The lateral pressure at the site of the stenosis must be the 
same as the lateral pressure in the artery distal"to the stenosis. 
The decrease in distal pressure, therefore, will cause the 
pressure in the stenosed segment also to decrease. This 
leads to the passive narrowing of the vessel lumen, which 
potentiates the with simultaneous decrease in (Carew 
et al., 1968). The exact role of collateral hemodynamics 
during distal vasodilatation is not clearly understood. 
One explanation of the unchanged R^ observed in these studies 
could be that they were functioning at their maximum capacity 
during the resting untreated state, and no significant im­
provement in would have occurred except during strenuous 
exercise (Khudaiberdyerv and Kulikov, 1971; Thulesius, 1972). 
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Serotonin 
Since its discovery in the blood serum by Rapport and 
his associates (1948), SRT has occupied a unique place as 
an important autacoid. Its role as a modulator of blood 
flow, following an arterial insult, has been investigated 
over the past 25 years (Bulle, 1957; Daicoff et al., 1968; 
Gladkova and Vasiliev, 1971; Schaub et al., 1976; Kordenat 
and Kezdi, 1979). SRT has variable actions in body tissues. 
It causes vasoconstriction of large arteries and vasodilata­
tion of smaller ones in low doses (Goodman and Oilman, 1975). 
Amphibaric actions of SRT can also be observed in various 
vascular beds depending upon their vascular tone (Page and 
McCubbin, 1953). 
To determine its actions, SRT was administered ia in 
the hind limb peripheral vascular bed of 6 dogs during arterial 
stenosis at 0, 95 and 100 percent levels (Table 2). Despite 
a slight improvement in peripheral blood flow, Q^, R^, R^ 
and Rg did not change significantly, suggesting no SRT 
effect on hind limb vasculature. Daugherty et al. (1968) 
also found nonsignificant variation in canine forelimb 
hemodynamics following ia or iv administration of SRT. The 
vasoconstriction attributed to SRT in the feline hind limb 
preparations, following thrombus associated occlusions, could 
have been due to interaction of SRT with PCs (Schaub et al.. 
Table 2. Vascular hemodynamics in the hind limb of the"dog before and after serotonin treatment 
Level of Hemodynamic variables (n=6) 
QC RC RP RS 
stenosis C SRT C_ SRT C SOT C SRT 
0 .43+.15 .48+.19 135.7+53 231.9+103 132.4+53 121.3+28.0 2.78+1.2 4.08+2.4 
.95 .54+.16 .48+.22 413.38+317 218+247 132.75+27 135.24+25.8 26.97+16.0* 21.8+10.6* 
100 1.03+.27* .82+.17* 118.28+44 111.66+30 151.9+36 123.1+23.82 3899+518^ 3750+484^ 
*P<. 05 within treatment in a group. 
^P<.05 within treatment in a group. 
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1976) . Its effects might have been mediated via TXAg 
released from the aggregated platelets (O'Donnel and Fiedel, 
1979). The resulting changes in the biochemical environment 
of the hind limb vasculature due to thrombus formation might 
also have potentiated the SRT effect reported in their 
studies (Rosenthal, 1972). Variation in the species of 
I 
experimental animals may also be a causal factor of the SRT 
effect. 
Methysergide 
To ascertain if SRT was being endogenously released 
during the process of occlusion, antagonists were used in the 
present study to determine SRT effects. METH, which compe­
titively inhibits SRT at its receptor site in vascular beds, 
was one of the inhibitors administered in 4 animals. The 
results obtained before methysergide treatment showed no 
significant change in Q (Pig. 9), R (Fig. 10), R (Fig. 11), 
^ c p 
and (Fig. 12), whereas R changed significantly at 95 
P s 
percent decrease in c.s. area (Pig. 13). A profound change 
in collateral and peripheral hemodynamics occurred following 
METH treatment. (Fig. 9) stopped flowing through the 
collateral bed and flow did not occur until 95 percent 
stenosis level was attained. During this period,the blood 
was being supplied to the affected collateral bed from the 
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Figure 9. Collateral blood flow during graded levels of 
femoral artery stenosis before and after methy-
sergide treatment 
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Figure 10. Collateral vascular resistance during graded levels 
of femoral artery stenosis before and after 
methysergide treatment 
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Figure 11. Peripheral vascular resistance during graded 
levels of femoral artery stenosis before and 
after methysergide treatment 
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Figure 12. Peripheral blood flow during graded levels of 
femoral artery stenosis before and after 
methysergide treatment 
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Figure 13. Femoral artery resistance during graded levels of 
stenosis before and after methysergide treatment 
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partially obstructed femoral artery. however, started 
flowing through the collateral bed when the femoral artery 
was completely occluded. (Fig. 10) remained undefined 
(negative value) until 95 percent stenosis, because of no 
flow situation in the collateral bed. It was significantly 
higher at 100 percent stenosis when compared to pretreated 
values. The peak negative value of R^, with a large standard 
error of the mean, was due to least negative value of 
(-.oi) in one animal. This increased R^ to a very large 
negative value was still nonsignificant as compared to 
lower levels of stenoses. R (Fig. 11) increased 2-3 times 
P 
from pretreated values following METH treatment. It remained 
higher and did not change significantly during graded stenoses. 
Q (Fig. 12) dropped significantly following METH treatment 
P 
and further decreased at 95 and 100 percent stenosis levels. 
Rg (Fig. 13) following METH did not change from those of pre­
treated values due to low flow rates through the stenosis 
before, and after, treatment. 
The decrease in and with concomitant increase in R^ 
and Rp observed in these studies may have been due to 
selective localized vasoconstriction produced by METH. 
Systemic arterial blood pressures were not affected during 
the experimental period. CO may have been the other factor 
to be influenced by METH, but it has been shown that even 
large doses of METH do not affect CO (Saxena, 1974). Similar 
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findings were reported by Graham (1964) in the femoral 
vascular bed and in the mesenteric and distal aortic regions 
by Saxena (1974). Ureles and Rob (1964) found an acute 
ischemia of the left foot, which was associated with the 
obstruction of the popliteal and dorsal pedis arteries as a 
result of METH induced arterial spasm. 
Selective vasoconstrictien following methysergide seen 
in these studies is difficult to explain. It may have been 
due to its direct action on the affected vascular bed or by 
the sensitization of the vascular tissue to the actions of 
the catecholamines (Dalessio, 1962; Saxena, 1972). However, 
the net effort of METH in a particular vascular bed is 
believed to be dependent upon pre-existing vascular tone 
(Saxena, 1974) despite its own feeble vasoconstrictive 
properties (Curran et al., 1967). Vasoconstriction may be po­
tentiated in the presence of ischemia or hypoxia. In the 
present study/ and R^ had attained a minimum value during 
the course of the experiment so that the collateral and 
peripheral beds were maximally dilated. The vasomotor tone 
under these conditions must also have attained its minimum 
value, which during METH treatment was reversed, and produced 
severe hemodynamic alterations in the hind limb vascular 
bed. 
The improvement in blood flow observed by Kordenat 
and Kezdi (1979) in thrombotically occluded coronary vessels 
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during METH treatment has no bearing on these studies. 
Occlusion in their studies was associated with thrombus and 
platelet aggregation, which must have released significant 
quantities of SRT, produced vasoconstriction, and potentiated 
the vasomotor tone of the vasculature. Under these condi­
tions, METH would have blocked the SRT induced vasoconstric­
tion, hence the net result would be vasodilatation and im­
provement in blood flow. Their studies also were in the 
coronary vascular bed, which possesses different vasoactive 
properties than hind limb vasculature. 
SRT following METH treatment did increase the collateral 
blood flow, which, however, was significantly lower than it 
was in pretreated animals even at severe stenosis levels 
(Ta&le 3) resulting in higher R_ values. R_ did not change j c P 
from pretreated values. The increase in during SRT in­
fusion can be attributed to its partial effectiveness at 
higher dose levels. Despite increase following METH 
I . 
treatment with SRT, it was still lower than in pretreated 
values. This may have been due to residual vasoconstrictive 
effect of METH in the canine hind limb vascular bed (Curran 
et al., 1967). 
Table 3. The vascular hemodynamics in the hind limb of the dog in methysergide pretreated animals 
following serotonin treatment 
Level of Hemodynamic variables (n=4) 
stenosis Q^(ml.sec-l) R^Cmm Hg-sec-ml-l) R (mm Hg-secml"^) Rs(mm Hg.sec.ml"^) 
CMTl SRT CMT SRT %MT SRT CMT SRT 
0 .58+.35 .17+. 08 724+647 245.6+633 90.32+23 120.33+21.0 2.7+.57 3.52+1.0 
95 .80+.31 .44+. 02* 70.7+26 339.32+146* 85.65+18 95.0+15 18.53+5.22 34.9+5.9*3 
100 0.96+.33 .98+. 23* 99.72+38 103.82+22 135.66+50 60.24+12 6382+2221* 7329+735** 
'CMT, control animals in methysergide group. 
* 
P<.05 between treatments in a group. 
^P<.05 within treatment in a group. 
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Parachlorophenylalanine 
PCPA is the most potent and selective depletor of SRT in 
brain and nervous tissue (Koe and Weissman, 1966). It in­
hibits SRT biosynthesis by inactivating tryptophan hydroxy­
lase, a rate limiting step in the synthesis of SRT (Bloom 
and Giarman, 1968). PCPA in this study was used to block the 
SRT at the neuronal level, to ascertain if the suggested vaso­
constriction by SRT (Sullenberger et al., 1959) was mediated 
via neurotransmission. 
Animals (n=4) subjected to PCPA treatment showed a marked 
improvement in at 95 and 100 percent stenosis levels, with 
concomitant decrease in R^ (Table 4). These changes, however, 
were not significantly different.from those observed under 
resting, untreated conditions. R remained unaffected during 
the course of the experiment and dropped to low values fol­
lowing ACH treatment. This decrease was due to distal 
vasodilatation caused by ACH infusion in the hind leg peripheral 
bed (Schwartz et al., 1979). These results reinforce previous 
observations that SRT is not the factor involved in the 
regulation of the blood flow. 
Table 4. Vascular hemodynamics in the hind limb of the dog following PCPA and ACH treatment 
Level of Hemodynamic variables 
stenosis =%— ZT n 
Qc(ml.sec ) R^(mm Hg.sec.ml ) Rp(mm Hg.sec.ml .) Rs (mm. Hq.sec.ml" ) 
PCPA ACH PCPA ACH PCPA AgH PCPA ACH 
0 .25+.1 .19+.1 440.5+182 252.8+97 126.4+16 60.3+11* .87+.18 1.01+0.71 
95 .43+.15^ .57+.l^ 129.8+60^ 112.13+40 131.73+24.5 80.52+15* 28.95+2.6^ 29.92+50^ 
h b** a * b b 
100 .81+.19 1.51+.13 56.49+15.8 46.61+8.4 134.6.16+50 50.87+7.2 3851+427® 6813+491 
* 
P<.05 between treatments in a group. 
** 
P<.01 between treatments in a group. 
a 
P<.05 within treatment in a group. 
^P<•05 within treatment in a group. 
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Reserpine 
RZP is an SRT antagonist. It releases all bound SRT 
from brain, platelets and body tissues. It inactivates or 
denatures the storage area at the receptor site and inter­
feres with its transport mechanism (Carlsson et al., 1957; 
Goodman and Oilman, 1975). 
Four animals were administered RZP and PCPA to eliminate 
SRT effects in the body. No significant change in collateral 
and peripheral hemodynamics was observed in these animals 
following R+PCPA treatment. A change did occur, however, 
when the animals were subjected to an elevated flow condition 
by continuous infusion of ACH (Table 5). The response with 
ACH was highly pronounced. increased markedly with simul­
taneous drop in R^ at 95 and 100 percent stenosis levels. 
R , though changed before and after ACH infusion, but the 
change was significant only at 95 and 100 percent stenosis 
levels. 
R was lower in PCPA treated animals following SRT 
P 
infusion. This was chiefly due to increased Q , since A'Ps 
P 
across the peripheral bed were not affected (Table 6). 
increased greatly at 100 percent stenosis in SRT administered 
animals. The marked increase in Q^, without simultaneous 
decrease in R^ before and after SRT infusion is difficult 
c 
to explain. It may have been due to increased APs ' • ' 
Table 5. Vascular hemodynamics in the hind limb of the dog after R+PCPA and ACH treatment 
Level of Hemodynamic variables 
stenosis (ml.sec ) Rc(mm Hg.sec.ml Rp(mm Hg.sec.ml (mm Hg.sec.ml 
R+PCPA ACH R+PCPA ACH R+PCPA ACH R+PCPA ACH 
** 
0 .41+.26 .85+.32 131.62+55 82.78+54 116.19+20 43.38+4.2 1.86+0.6 0.7+.19 
** * ** a a 95 .48+.16 .99+.18 125.5+32 48+15 140.0+17 50.67+6.7 38.11+15® 32.5+13^ 
100 .57+.08 1.39+.33* 79.9+15 45.7+9* 186.6+42 63.0+11* 4768+1470^ 4465+900^ 
* 
P<.05 between treatments in a group. 
** 
P<.01 between treatments in a group. 
^P<.05 within treatment in a group. 
^P<.05 within treatment in a group. 
Table 6. Vascular hemodynamics in the hind linda of the dog after PCPA ^d SRT treatments 
Iievel of Hemodynamic variables 
stenosis Qctmi.geç ^c(mm Hg.sec.ml Rp(mm Hg.sec.ml Rs(mm Hg.sec.ml 
PCPA SRT PCPA SRT PCPA SRT PCPA SRT 
* 
0 .25+.12 .3+.1 450.5+182 279.6+127 126.4+16.8 60.14+11 1.12+.7 1.44+.5 
95 .43+.15^ .57+.1^ 129.77+60* 112.13+40 131.73+24 80.55+15* 28.95+2.6^ 29.92+5.0* 
100 .81+.19^ 1.51+.12^ 56.5+15 44.1+9.8 151.64+40 50.87+ 7* 3856+425^ 6836+467^ 
* 
P<.05 between treatments.in a group. 
** 
P<.01 between treatments in a group. 
a 
•p<.05 within treatment in a group. 
^P<.05 within treatment in a group. 
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across the collateral bed at severe stenosis levels. 
The response obtained after SRT administration in 
R+PCPA treated animals (Table 7) was similar to that ob­
tained in PCPA treated animals. was higher at all stenosis, 
levels and R^ did not change significantly, perhaps because 
of the larger doses of SRT (30 pg/Kg/Min) infused in the 
present group of animals. The larger SRT doses may have over­
ridden the PCPA and R+PCPA effect and, in some way, may have 
influenced the collateral as well as peripheral hemodynamics. 
To determine if SRT was one of the vasoactive agents 
being released during the process of occlusions, blood samples 
were collected at 0, 95 and 100 percent decrease in the lumen 
c.s. area in resting untreated, METH, PCPA and R+PCPA treated 
groups of animals (Table 8). No significant differences in 
SRT contents were found to exist in any of the groups be­
fore SRT infusion, although the concentration was lower in 
PCPA and R+PCPA treated animals. SRT levels, however, were 
3 times higher at all levels of stenosis following SRT in­
fusion in these groups. 
The lack of variation in SRT concentration at varying 
levels of stenosis in different groups of animals before SRT 
administration is a result that conflicts with the findings 
of Sullenberger et al. (1959); Schaub et al. (1977a) and 
Kordenat and Kezdi (1979). They observed that significant 
quantities of SRT were released and suggested that intravascular 
Table 7. Vascular hemodynamics in the hind limb of the dog after R+PCPA and SRT treatments 
Level of Hemodynamic variables 
stenosis (mi.sec R^(mm Hg.sec.ml Rp(mm Hg.sec.ml Rg (mm Hg.sec.ml 
R+PCPA SRT R+PCPA SRT R+PCPA SRT R+PCPA SRT 
* 
0 .44+.23 .85+.32 218.37+122 82.78+54 116.19jJ20.7 40.38+4.2 1.86+.6 0.77+.19 
95 .48+.16 .99+.18* 125.4+31.9^ 47.97+15^ 140.95+17 . 50.17+6** 26.8+4.0^ 32.96+5.5^ 
100 .54+.08 1.39+.33* 80+15^ 45.7+9^ 186+41.9 62.9+11* 3576+584^ 4611+708^ 
* 
P<.05 between treatments in a group. 
** 
P<.01 between treatments in a group. 
^P<.05 within treatment, in a group. 
^P<.05 within treatment in a group. 
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Table 8. The serotonin contents In the canine blood during graded 
stenoses following treatments with various agonists and 
^tagonlsts 
Group Treatment Serotonin contents (yg/ml) 
number 0% Stenosis 95% Stenosis 100% Stenosis 
G1 C .62 + .06 .56 + .07 .51 + 
m
 
o
 
SRT 2.03 + .3* 1.91 + .4* 1.94 + .45* 
G2 C . .63 + .1 .50 + .08 .58 + .08 
METH .65 + .11 .6 + .09 .53 + .1 
SRT 1.25 + .3* 1.02 + .3* 1.05 + .35* 
G3 PCPA .38 + .1 .4 + .1 .37 + .1 
ACH .5 + .2 .53 + .07 .48 + .06 
SRT 1.41 + .14* 1.34 + .2* 1.48 + .2* 
G4 R+PCPA .37 + .04 .39 + .03 .41 + .04 
ACH .49 + .09 .51 + .05 .43 + .03 
SRT 1.49 + .3* 1.32 + .3* 1.48 + .3* 
* 
P<.05 between treatments within a group. 
thrombosis, with its attendant cell damage and platelet 
aggregation, may have been the cause. The differences in 
vascular beds and experimental animal species in their 
studies, is another probable contributing factor for the 
variation in these results. 
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Indomethacin 
PCs are local hormones and are released by almost every 
tissue in the body, including the blood vessel wall. Stimuli 
for release include mechanical damage, surgical trauma, 
endothelial cell damage, and decreased oxygen tension. PGIg 
is constantly released from the vessel wall due to platelet 
and vessel wall interaction. The PGIg synthetase is located 
in the endothelial cells of the vessel wall in an inactive form. 
The moving platelets in circulating blood, when they come 
into contact with the vessel wall, activate PGIg synthetase 
and result in PGI^ biosynthesis. The PGIg does not allow 
deposition of platelets to the vessel wall under normal flow 
conditions (Owen et al., 1975; Dusting et al., 1977; Moncada 
et al., 1977a, 1978). During endothelial cell damage, 
disruption in the synthesis of PGIg occurs and causes 
platelet deposition, platelet aggregation, thrombus forma­
tion and TXAg release (Horie et al., 1978; Moncada et al., 
1976). 
Within a wide range of perfusion pressures and arterial 
oxygen concentrations, hind limb vascular blood flow adjusts 
automatically to meet the metabolic demands of the tissues 
in the region. The adjustment is a result of endogenous 
release of vasoactive PGs and other substances. The role 
of PGs in the regulation of blood flow is well-documented 
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(Alexander et al., 1975; Needleman and Kaley, 1978). PGI^ 
is the most predominantly released substance during arterial 
occlusion (Moncada et al., 1977a; Serneri et al., 1980). 
However, during endothelial cell damage and thrombus forma­
tion, TXAg is the predominant vasoactive compound (ElliS; 
et al., 1976; Moncada et al., 1976). 
To ascertain the role of these vasoactive PGs in the 
regulation of blood flow during an arterial occlusion, and to 
identify the vasoactive PGs, INDO was used to antagonize the 
endogenously released PGs. INDO inhibits PG biosynthesis 
during the initial stages of biosynthetic pathway at the 
cyclo-oxygenase level (Flower, 1974). 
Animals (n=4) treated with INDO showed paradoxical 
changes from pretreatment levels in collateral and peripheral 
hemodynamics. ceased during partial occlusions (Pig. 14). 
At this point, blood to the thigh region was being supplied 
from the partially obstructed femoral vessel. This redistribu­
tion of flow through the stenosis caused a severe decrease in 
Qp (Fig. 17) with concomitant increases in (Fig. 16). 
started flowing through the collateral bed at 100 percent 
stenosis and was still significantly lower than it was at 
the pretreated level. (Fig. 15) was significantly higher 
at this point. R^ (Fig. 18)^ however, did not change in 
pre- and post-treated animals due to insignificant variations 
in Qg between the treatments. 
Figure 14. Collateral blood flow during graded levels of 
femoral artery stenosis before and after 
indomethacin treatment 
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Figure 15. Collateral vascular resistance during graded 
levels of femoral artery stenosis before and 
after indomethacin treatment 
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Figure 16. Peripheral vascular resistance during graded 
levels of femoral artery stenosis before and 
after indomethacin treatment 
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Figure 17. Peripheral blood flow during graded levels of 
femoral artery stenosis before and after 
indomethacin treatment 
Figure 18. Femoral artery resistance during graded levels 
of stenosis before and after methysergide 
treatment 
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These findings confirm the results of Afonso et al. 
(1974), Alexandar et al. (1973, 1975), and Owen et al. 
(1975), who reported that the regulatory role of hypoxia-
induced PCs release was blunted by INDO and led to a marked 
decrease in reactive hyperemic response and PG biosynthesis. 
Hintz and Kaley (1977) observed that PG synthetase inhibition 
by INDO was associated with decreased peak vasodilatation 
and decreased hyperemic response (Kramer et al., 1976). 
Similar observations were made by O'Beaty and Donald (1979) 
and Rosenblum et al. (1980) during their studies on femoral 
and mesenteric vascular beds, respectively. 
Although the exact mechanism of INDO action in a vascular 
bed is yet to be characterized, as an antagonist its inhibi­
tion of PG synthesis at the cyclo-oxygenase level is well 
documented. It inhibits PG biosynthesis by inactivating 
cyclooxygenase enzyme. Its direct vasoconstrictive effects 
via increased catecholamines and its role in modulation of 
vascular tone have also been suggested (O'Beaty and Donald, 
1979). 
In the present study, R and R were at their minimum 
c p 
value before, and attained 2-3 times higher value following, 
INDO treatment. Such a pronounced change could only have 
occurred by the inhibition of vasodilator PGs, chiefly PGIg. 
This may have been released during experimental preparations 
and occlusions. However, the selective vasoconstrictor effect 
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of INDO, either direct or potentiated by catecholamines, 
cannot be ruled out. 
Imidazole 
Critical stenosis has been associated with platelet 
aggregation and subsequent cyclical reductions in blood flow 
in femoral arteries (Folts and Rowe, 1980) and in coronary 
arteries (Folts et al., 1976; Cappuro et al., 1980; Uchida 
et al., 1980). Platelet activation and aggregation cause 
the release of vasoactive PGs, principally TXAg, which causes 
vasoconstriction in the arterial bed (Ellis et al., 1976; 
Moncada et al., 1976). 
IMZ, as a selective inhibitor of TXA^, was administered 
to ascertain if critical stenosis was associated with platelet 
.aggregation and TXAg release in these preparations. TXAg 
has been implicated in the inhibition of collateral recruit­
ment during different vascular insults (Needleman et al., 
1977b; Helenski et al., 1980). Imidazole acts by in­
activating the TXAg synthetase and does not allow the conver­
sion of PGGg or PGHg to TXAg, whereas the synthesis of other 
PGs continues via their normal synthetic pathways (Moncada 
et al., 1977b). 
IMZ treatment (n=4) did not produce a significant varia­
tion in vascular hemodynamics from the level of hemodynamics 
in pretreated animals. (Fig. 19) did not change 
Figure 19. Collateral blood flow during graded levels of 
femoral artery stenosis before and after 
imidazole treatment 
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significantly until a 100 percent decrease in the c.s. area 
was achieved. (Fig. 20) and R^ (Fig. 21) remained at 
lower values during the experiment, suggesting a maximum 
vasodilatation at the beginning of the experiment. The 
variable responses at 90 percent stenosis in R^ were non-
significantly different from other values because of a 
larger standard error of the mean. This response occurred 
because in one of the animals the peripheral bed was not 
maximally dilated and showed no.Q^ and lower at 90 
percent stenosis level. This lower value not only in­
creased the R , but also produced a great variation within 
P 
the group itself. The insignificant drop in R was due to 
increased pressure gradients across the collateral bed. R^ 
(Fig. 22) changed significantly at 90 percent stenosis, 
whereas at lower levels of stenosis the difference was 
insignificant. 
Similar findings were reported by Uchida and Murao 
(1979) following IMZ treatment in coronary arteries. How­
ever, the findings of Helenski et al. (1980) revealed im­
proved following INDO treatment. These findings have no 
bearing on the present study or on those of Uchida and Murao 
(1979). Subacute preparations and their association with 
thrombus predominantly would have released TXAg as a vaso­
active PG in their studies. Due to absence of cyclical re­
ductions of flow through, and pressure down stream from the 
Figure 20. Collateral vascular resistance during graded 
levels of femoral artery stenosis before 
and after imidazole treatment 
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Figure 21. Peripheral vascular resistance during graded 
levels of femoral artery stenosis before and 
after imidazole treatment 
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Figure 22. Femoral artery resistance during graded levels 
of stenosis before and after imidazole treat­
ment 
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stenosis coupled with insignificant response to imidazole 
treatment, one may assume that platelet aggregates and TXA^ 
were not involved in the regulation of blood flow in these 
studies. 
DCFA Occlusion 
It was hypothesized in this study that DCFA, by virtue 
of its extensive anastamosing connections with vessels both 
in ascending and descending directions, was an important 
collateral recipient artery. An attempt was made to quantify 
the blood flow in the DCFA both during resting and elevated 
flow conditions. Animals(n=8) with DCFA occlusion (Table 9) 
showed a marked decrease in blood flow during resting and 
elevated flow conditions. This, however, was not signifi­
cantly different at a 95% decrease in lumen c.s. area. 
on the other hand remained unchanged during DCFA occlusion. 
These findings are in agreement with the findings of Kubicka 
et al. (1979), who observed that there was no significant 
variation in collateralization following the ligation of 
medial sacral, II, and DF arteries. In this study, therefore, 
the carrying capacity of the DCFA is quantitatively esti­
mated, which despite a slight decrease, did not significantly 
change under elevated flow conditions. 
Table 9. The blood flow through the femoral artery and collateral vascular bed 
during graded stenoses with and without DCFA occlusion under normal 
and elevated flow conditions 
Treatment Qg(ml.sec-^) (ml.sec"^) 
0% 95% 100% 0% 95% 100% 
Control 
WDO 1.12 + .08 .61 + .04^ .36 + .02 .52 + .2 .93 + .2 ^ 
DO .78 + .06* .63 + .04 .19 + .07 .26 + .11 .64 + .08^ 
ACH 
WDO 2.65 + .37 1.17 + .3 ; .2 + .47 . 66 + .34 1.51 + .36^ 
DO 1.68 + .23** .9 + .13 .16 •+ .07 .65 + .15^ 1.09 + .05^ 
WDO = DCFA patent. 
DO = = DCFA occluded. 
ACH = acetylcholine. 
P<.05 between treatments in a group. 
** 
P<.05 between treatments in a group. 
P<. 05 within treatment in a group. 
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SUMMARY AND CONCLUSIONS 
The objective of the present investigation was to 
determine the influence of endogenously released vasoactive 
substances on the canine hind limb vasculature during graded 
arterial stenoses. The study was conducted on 28 mongrel 
dogs weighing between 22 to 36 Kg. Animals were divided into 
6 groups (G1-G6) which received either agonist (Serotonin 
or Acetylcholine) or antagonist (Methysergide, Parachloro-
phenylalanine, Reserpine and Parachlorophenylalanine, Indo-
methacin or Imidazole) or both. The collateral and 
peripheral hemodynamics were measured during partial and 
complete occlusions of the femoral artery. 
Resting, untreated animals (GI) did not show a signifi­
cant variation in collateral and peripheral resistances fol­
lowing partial or complete occlusion of the femoral artery. 
Peripheral resistance dropped to less than 50 percent of 
resting level under elevated flow conditions. The collateral 
blood flow and resistance remained unchanged during this 
period. No serotonin effect was seen on hind limb vasculature. 
Methysergide treatment (GII) invoked a 2-3 fold increase in 
collateral and peripheral resistances, and collateral blood 
flow completely ceased during partial stenoses. During this 
period, nutritional blood flow was supplied to the collateral 
bed from the partially obstructed femoral vessel. This 
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redistribution of flow caused a severe drop in flow supplied 
to the peripheral bed distal to stenosis. The reduction was 
presumably due to the localized vasoconstrictive effects of 
methysergide in a maximally dilated vascular bed. The fact 
that collateral and peripheral hemodynamics were the same 
as in animals treated with either parachiorophenylalanine or 
reserpine and parachlorophenyialanine (G III and IV) 
suggests that serotonin was not involved in producing the 
vascular responses observed in these preparations. 
Indomethacin treatment caused paradoxical changes in 
the hind limb vasculature with peripheral resistances in­
creasing 2-3 fold. No blood flowed through the collateral 
vascular bed during partial occlusion of the femoral artery. 
The collateral vascular bed, however, received nutritional 
flow from the partially constricted femoral artery. Re­
distribution of flow, therefore, caused severe reductions in 
the rate of blood flow to the hind leg distal to occlusion 
and significantly increased peripheral resistance over the 
resistance of the untreated animals. High resistances and 
low blood flows observed during indomethacin treatment could 
be attributed to the treatment's inhibition of vasodilatory 
prostaglandins (principally PGIg) that might have been 
released during graded stenoses. However, the nonspecific 
localized vasoconstrictor effects of indomethacin and its 
direct effect upon vascular tone in the region cannot be 
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ruled out. 
Imidazole treatment produced no effect on the canine 
hind limb vasculature, probably due to lack of platelet 
aggregation and thromboxane Ag release in these studies. 
The distal caudal femoral artery (DCFA) carried 30 
percent of the femoral artery blood flow under normal condi­
tions. Collateral blood flow did not change significantly 
when DCFA was occluded. This study quantitated for the 
first time, the blood flow carried by the DCFA from the 
femoral artery. It is also shown that DCFA is not the only 
collateral recipient vessel present in the hind limb. Other 
vessels which either carry collateral blood flow and empty 
into patent DCFA, or drain distally, when occluded, may be 
present. The possibility that these vessels recruit additional 
collateral channels following DCFA occlusion cannot be ruled 
out. 
The studies conclude that in these preparations serotonin 
or thromboxane Ag were not involved in producing vascular 
responses and were not released during the process of 
occlusion. In contrast, vasoactive prostaglandins (principally 
PGIg) were believed to be released and played the regulatory 
role in the maintenance of the blood flow to the hind limb 
vasculature. Their inhibition by indomethacin inhibited 
this regulatory response. 
Before these results can be safely generalized, further 
115 
study is needed to characterize the underlying biochemical 
regulatory mechanisms. In particular, the effects of 
tissue and blood oxygen levels on prostaglandin biosynthesis 
and the interaction between prostaglandins, hormones and 
neurotransmitters, need to be more clearly understood. 
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FUTURE RESEARCH 
The present investigation has given some insights into 
the possible release of vasoactive regulators including the ( 
problems associated with it. Future studies, therefore, 
could be planned in different phases with an ultimate ob­
jective of developing a therapeutic agent to counter the 
obstructive obliterans disease in human beings as a re­
placement for surgical intervention. 
Phased investigations could proceed as follows: 
1. a) The present study could be redesigned,(involving 
less invasiveness and more animals) and dupli­
cated with a direct approach of assaying the 
release of vasoactive PCs, chiefly PGIg. 
b) If PGIg assays reveal significantly higher levels 
following partial occlusions, 15-hydroperoxy-
arachidonic acid could be used as the antagonist 
rather than indomethacin which is believed to have 
other effects, apart from PG biosynthesis 
inhibition. 
c) If possible, tissue oxygen tension could be 
measured in the affected region and correlated 
with blood flow and PGIg release. 
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2. Endeavors then could be made to successfully produce 
and reproduce an acute experimental arterial 
thrombosis, in an effort to simulate the obstructive 
obliterature disease in human beings. This phase 
could be reinforced with steps b and c in phase 1 
except that TXAg, SRT in addition to PGIg could 
be assayed and subsequently inhibited. 
3. These studies should include the use of inhibitors 
in a search for a satisfactory therapeutic agent 
to overcome a thrombotic crisis without producing 
any side effect in the system. 
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APPENDIX A 
The polygraph was electrically zeroed and balanced at 
the beginning of each experiment. It was necessary to avoid 
the offsets in determination of the calibration factors 
and pressure and flow measurements. The calibrations 
were obtained from the Pdp8e Lab. digital computer. The 
calibration factor was determined in mm Hg pressure equi­
valent to 1 volt of electrical output for each transducer. 
To obtain reliable estimates of pressure calibration, a 
manometer filled up to 2000 mm HgO was used. A computer 
program which converted mm HgO pressure into mm Hg pressure 
was used for calibration. Calibration factors were obtained 
over a wide range of pressures applied simultaneously to all 
the five pressure transducers. All transducers showed a 
close linear response for pressures ranging between 1000 and 
2000 mm HgO. There was nonlinearity in response of trans­
ducers when pressures were dropped to 500 mm H^O and less. 
The calibration factor obtained in the lower range was 
used for the one transducer which detected venous pressure. 
The calibration factors for the remaining four transducers 
were measured in systemic arterial blood pressure ranges 
(1900-2000 mm HgO). In an effort to obtain error free and 
truly representative values, 4-5 close readings for each 
transducer were averaged. Before the data were obtained from 
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an experimental animal, using these calibration factors, known 
applied pressures were compared with those obtained from the 
transducers. If the two values fell within +1 mm Hg pressure 
of each other, the calibration factors were considered accurate 
and reliable for data acquisition purposes. 
EMP transducers were calibrated over a wide range of 
steady flow rates with a constant pressure head resérvoir 
which contained blood from the experimental animal. The 
calibration set-up contained both EMF transducers (Q , Q j 
s p 
in extracorporeal circuits with a flow controlling device 
between the collecting point and the bypass system. Flow 
rate was measured by a timed collection in a graduated 
cylinder. Flow was varied by increasing or decreasing the 
resistance as and when required. The calibration factors 
were estimated at different flow rates. Four to five close 
readings for each flow probe were averaged. A known timed 
collection of blood flow was compared with that of EMF, using 
these calibration factors. If the results were within + .05 
ml/sec, the calibration factors were considered reliable and 
were used for data acquisition from the experimental animal. 
137 
APPENDIX B 
Table Bl. Fluid dynamics in the arterial and venous bypasses of the extra­
corporeal perfusion apparatus 
Arterial bypass 
Flow 
(ml/sec) 
Resistance 
mm Hg.sec.]ml -1 
Venous bypass 
Flow 
(ml/sec) 
Resistance 
mm Hg*sec»ml -1 
0 . 6 2  
1.73 
3.57 
3.64 
4.65 
5.22 
5.80 
0.64 
1.20 
1.99 
2 . 0 8  
2.48 
2.73 
2.96 
0.95 
2.33 
3.33 
3.73 
3.87 
5.00 
6 . 2 8  
0.25 
0.75 
1.04 
1.08 
1.09 
1.39 
1.62 
Table B2. Fluid dynamics during graded stenoses in the stenotic arterial 
segment and total bypass circuit 
Level of 
stenosis 
Bypa ss Arterial segment 
^1 
(mm Hg) 
^2 
(mm Hg) 
. Flow 
ml/sec. 
Resistance 
mm Hg_, 
sec-ml" 
^1 
(mm Hg) 
^2 
(mm Hg) 
Flow 
ml/sec. 
Resistance 
mm Hg_^ 
sec sml~ 
0 39.29 12.42 6.84 3.93 35.38 29.59 7.15 0.81 
60 39.63 12.55 6.86 3.95 35.62 29.80 7.19 0.81 
80 41.51 9.33 6.30 5.11 38.25 23.84 6.57 2.19 
90 44.91 1.10 5.22 8.39 42.91 11.08 5.17 6.16 
95 53.34 6.84 1.62 28.70 52.68 10.68 1.59 24.43 
100 54.12 3.55 0.14 361.21 55.39 6.06 0.24 205.54 
Table B3. Flow rates and Reynolds numbers in bypass systems 
Arterial bypass Venous bypass 
Flow ml/sec Reynolds # Flow ml/sec Reynolds # 
0.64 450 0.95 669 
1.62 704 2.33 1640 
1.73 814 3.33 2344 
3.57 2513 3.73 2626 
3.64 2562 3.87 2724 
4.65 3274 5.00 3520 
5.22 3675 6.28 4421 
5.80 4083 
1.41 
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Figure Bl. Resistance and flow relationship of arterial 
segment in the bypass, arterial bypass and 
venous bypass circuits 
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APPENDIX C. 
Serotonin analysis; 
3 ml of whole blood was diluted with 5 ml of distilled 
water to hemolyze erythrocytes (henceforth it will be . 
referred as a sample) 
1 ml of 10 percent ZnSO^ solution was then added and 
sample mixed 
This was followed by addition of .5 ml IN NaOH. The 
sample was mixed again 
The sample was then centrifuged at 2500-3000 rpm 
for 10 minutes 
The supernatant was harvested 
1 ml of supernatant was added to a tube containing 10 
ml of n-butanol 
The sample was centrifuged for 5 minutes 
The supernatant was isolated once again 
2.5 ml of supernatant was shaken mechanically with 
7.5 ml of n-heptane and .2 ml of .IN HCl 
The mixture was then centrifuged for 10 minutes 
The butanol-heptane interphase was the aspirated and 
discarded 
The remaining aliquot of extracted serotonin (.1-.15 
ml) was then allowed to react with .6 ml of ortho-
phaldialdehyde (OPT) (4 mg/100 ml ION HCl) which resulted 
in a fluorescent derivative in boiling water both for 
15 minutes 
The fluorescence was read at 360 my activation spectrum 
and 470 my emission spectrum along with standard 
containing known concentration of serotonin after 
cooling in tap water 
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Serotonin concentration was then calculated by the 
following formula 
Fluorescence of 
Serotonin (ug/ml)' = piuSrelceScl o£ ^ std. conch. 
the standard 
X dilution 
